A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

Autor: Demoen L; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium., Matthijssens F; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium., Reunes L; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium., Palhais B; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium., Lintermans B; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium., T'Sas S; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Fijalkowski I; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Leukemia Therapy Resistance Laboratory, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium., Taminau J; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Department Biomedical Molecular Biology, 9000 Ghent University, Ghent, Belgium., Akele MZ; Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium., Van Belle S; Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium., Taghon T; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; T Cell Team Taghon, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Deforce D; Laboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium., Van Nieuwerburgh F; Laboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium., Berx G; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Department Biomedical Molecular Biology, 9000 Ghent University, Ghent, Belgium., Ntziachristos P; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Leukemia Therapy Resistance Laboratory, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium., Debyser Z; Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium., Durinck K; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Pediatric Precision Oncology Lab, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium., Pieters T; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium.; Leukemia Therapy Resistance Laboratory, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium., Goossens S; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Van Vlierberghe P; Lab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.

Publikováno v: Science advances [Sci Adv] 2024 Nov; Vol. 10 (44), pp. eado6765. Date of Electronic Publication: 2024 Nov 01.

Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.

Autor: De Coninck S; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent., De Smedt R; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent., Lintermans B; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent., Reunes L; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, 9000 Ghent., Kosasih HJ; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia; School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW., Reekmans A; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent., Brown LM; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia; School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW., Van Roy N; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Lab for Translational Oncogenomics and Bioinformatics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Pediatric Precision Oncology Lab, Department of Biomolecular Medicine, Ghent University, 9000 Ghent., Palhais B; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, 9000 Ghent., Roels J; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent., Van der Linden M; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Pathology, Ghent University and Ghent University Hospital, 9000 Ghent., Van Dorpe J; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Pathology, Ghent University and Ghent University Hospital, 9000 Ghent., Ntziachristos P; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, 9000 Ghent., Van Delft FW; Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne., Mansour MR; Department of Developmental Biology and Cancer, Institute of Child Health, University College London., Pieters T; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, 9000 Ghent., Lammens T; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, 9000 Ghent., De Moerloose B; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, 9000 Ghent., De Bock CE; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia; School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW., Goossens S; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent. steven.goossens@ugent.be., Van Vlierberghe P; Lab of Normal and Malignant Hematopoiesis, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), 9000 Ghent.

Publikováno v: Haematologica [Haematologica] 2024 May 01; Vol. 109 (5), pp. 1373-1384. Date of Electronic Publication: 2024 May 01.

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.

Autor: Provez L; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Putteman T; Taghon Laboratory, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Landfors M; Department of Medical Biosciences, Umeå University, 90185 Umeå, Sweden., Roels J; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.; Taghon Laboratory, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Reunes L; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., T'Sas S; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Van Loocke W; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Lintermans B; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., De Coninck S; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Thenoz M; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Sleeckx W; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium.; Hematology Department, Ghent University Hospital (UZGent), 9000 Ghent, Belgium., Maćkowska-Maślak N; Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznań, Poland., Taghon T; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.; Taghon Laboratory, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Mansour MR; Leukaemia Biology Research Group, Department of Heamatology, University College London Cancer Institute, London WC1E 6DD, UK.; UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK., Farah N; Leukaemia Biology Research Group, Department of Heamatology, University College London Cancer Institute, London WC1E 6DD, UK., Norga K; Paediatric Oncology at Antwerp University, 2000 Antwerp, Belgium., Vandenberghe P; Department of Human Genetics, Leuven University, 3000 Leuven, Belgium., Kotecha RS; Leukaemia Translational Research Laboratory, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth 6009, Australia.; Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth 6009, Australia.; Curtin Medical School, Curtin University, Perth 6102, Australia., Goossens S; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.; Unit for Translational Research in Oncology, Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium., Degerman S; Department of Medical Biosciences, Umeå University, 90185 Umeå, Sweden.; Department of Clinical Microbiology, Umeå University, 90185 Umeå, Sweden., De Smedt R; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Van Vlierberghe P; Normal and Malignant Hematopoiesis Laboratory, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jan 20; Vol. 15 (3). Date of Electronic Publication: 2023 Jan 20.

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Autor: Pieters T; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., T'Sas S; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Vanhee S; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium., Almeida A; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Driege Y; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Roels J; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Van Loocke W; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Daneels W; Cancer Research Institute Ghent, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.; Department of Hematology, Ghent University Hospital, Ghent, Belgium., Baens M; Center for Innovation and Stimulation of Drug Discovery Leuven, Leuven, Belgium., Marchand A; Center for Innovation and Stimulation of Drug Discovery Leuven, Leuven, Belgium., Van Trimpont M; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Matthijssens F; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Morscio J; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Lemeire K; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Lintermans B; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Reunes L; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Chaltin P; Center for Innovation and Stimulation of Drug Discovery Leuven, Leuven, Belgium.; Center for Drug Design and Discovery, Catholic University of Leuven, Leuven, Belgium., Offner F; Cancer Research Institute Ghent, Ghent, Belgium.; Department of Hematology, Ghent University Hospital, Ghent, Belgium., Van Dorpe J; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.; Department of Pathology, Ghent University Hospital, Ghent, Belgium., Hochepied T; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Berx G; Cancer Research Institute Ghent, Ghent, Belgium.; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Beyaert R; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Staal J; Center for Inflammation Research, Flemish Institute for Biotechnology, Ghent, Belgium.; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Van Vlierberghe P; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium., Goossens S; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium.; Cancer Research Institute Ghent, Ghent, Belgium.; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2021 Oct 04; Vol. 218 (10). Date of Electronic Publication: 2021 Aug 18.

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

Autor: Matthijssens F; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Sharma ND; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA., Nysus M; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA., Nickl CK; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA., Kang H; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.; Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA., Perez DR; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.; University of New Mexico Center for Molecular Discovery, Albuquerque, New Mexico, USA., Lintermans B; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Van Loocke W; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Roels J; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Peirs S; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Demoen L; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Pieters T; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Reunes L; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Lammens T; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium., De Moerloose B; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium., Van Nieuwerburgh F; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium., Deforce DL; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium., Cheung LC; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia., Kotecha RS; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia., Risseeuw MD; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium., Van Calenbergh S; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium., Takarada T; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Yoneda Y; Department of Pharmacology, Osaka University Graduate School of Dentistry, Suita, Japan., van Delft FW; Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Lock RB; Children's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales, Sydney, New South Wales, Australia., Merkley SD; Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA., Chigaev A; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.; University of New Mexico Center for Molecular Discovery, Albuquerque, New Mexico, USA., Sklar LA; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.; University of New Mexico Center for Molecular Discovery, Albuquerque, New Mexico, USA., Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Loh ML; Department of Pediatrics, Benioff Children's Hospital, UCSF, San Francisco, California, USA., Winter SS; Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, Minnesota, USA., Hunger SP; Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Goossens S; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium., Castillo EF; Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA., Ornatowski W; Department of Medicine, University of Arizona, Tucson, Arizona, USA., Van Vlierberghe P; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Matlawska-Wasowska K; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2021 Mar 15; Vol. 131 (6).